• Review • Previous Articles Next Articles
XU Wen-di, TAO Tao, LIU Wei
Online:
Published:
Abstract:
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women at childbearing age. The main manifestations include hirsutism and acne due to hyperandrogenism, menstrual disorders, as well as infertility caused by anovulation or oligo-ovulation. Furthermore, the risks of suffering from adverse cardiovascular events and metabolic disorders increase significantly for patients with PCOS. Clinically, the internal medicine treatments of PCOS include diet and lifestyle interventions, anti-androgens, and improving metabolic syndrome. Nowadays, the metabolic treatment that integrates multiple therapies such as improving the insulin resistance, regulating lipids, and reducing the inflammatory has gradually become a trend. Metformin, berberine, glucagon-like peptide -1 (GLP-1) receptor agonist, and other drugs that can adjust the metabolic syndrome have been widely used for the treatment of PCOS and obtained multiple curative effects. This paper reviews advances of the treatment of metabolic abnormalities for patients with PCOS.
Key words: polycystic ovary syndrome, metabolic therapy, lifestyle intervention, medication
XU Wen-di, TAO Tao, LIU Wei. Advances of treatment of metabolic abnormalities for patients with polycystic ovary syndrome[J]. , doi: 10.3969/j.issn.1674-8115.2015.09.033.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2015.09.033
https://xuebao.shsmu.edu.cn/EN/Y2015/V35/I9/1407